In some diseases such as atherosclerosis, osteoarthritis, and acute lung injury, overexpression of NLRC5 can inhibit the activation of inflammation, which may be linked to the negative regulatory of NLRC5 on interferon (IFN)-I and nuclear factor-kappaB (NF-κB)23–25. This evidence concerns the gene NLRC5 and medical procedure.